JMP Securities analyst Silvan Tuerkcan initiated coverage of enGene (ENGN) with an Outperform rating and $18 price target enGene is a clinical-stage biotechnology company focused on developing novel mucosal targeted gene therapies utilizing a proprietary Dually Derivatized Oligochitosan platform, which enables localized delivery of multiple gene cargos directly to mucosal tissues and other organs, the analyst tells investors in a research note. The firm expects an expansion of therapeutics utilization in non-muscle invasive bladder cancer ahead of cystectomy and an increase in demand for intravesically-instilled therapies.
Don't Miss our Black Friday Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ENGN:
- enGene files to sell 46.98M common shares, 6.29M warrants for holders
- enGene files $300M mixed securities shelf
- enGene Holdings Secures $60 Million for Genetic Medicines
- enGene Holdings Announces Key Executive Appointments
- enGene CTO Anthony Cheung transitions to CSO, Joan Connolly to succeed
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
